ArticleAmerican journal of translational research2025
Efficacy and prognosis of concurrent chemoradiotherapy in the management of recurrent cervical cancer: a retrospective study.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective study aimed to evaluate the efficacy of concurrent chemoradiotherapy (CCRT) in the treatment of recurrent cervical cancer (RCC) and its effect on patient prognosis.
methodsA total of 106 RCC patients, treated at Nanfang Hospital and Southern Medical University from January 2015 to January 2019, were retrospectively analyzed. Of these, 56 patients who received CCRT served as the research group, while 50 patients treated with radiotherapy alone formed the control group. Outcomes compared between groups included treatment efficacy, tumor-free survival (TFS), 5-year overall survival (OS) rate, incidence of adverse reactions, serum tumor marker levels (carbohydrate antigen 15-3 [CA15-3], squamous cell carcinoma antigen [SCCA], and carcinoembryonic antigen [CEA]) and quality of life at 6 months post-treatment. Prognostic factors for poor outcomes were also analyzed.
resultsCompared to the control group, the CCRT group exhibited significantly higher total response rate, prolonged TFS, improved 5-year OS rate, and better quality of life at 6 months post-treatment (all P<0.05). Serum levels of CA15-3, SCCA, and CEA decreased significantly post-treatment in the CCRT group and were lower than those in the control group (all P<0.05). Although the incidence of adverse reactions in the research group was slightly higher, the difference was not significant (P>0.05), and all side effects were alleviated after treatment. Multivariate analysis identified age, pathologic stage, treatment response, and treatment modality as independent prognostic risk factors (all P<0.05).
conclusionsCCRT demonstrated superior efficacy, favorable prognosis, and low complication rate in the treatment of RCC. It effectively suppressed serum tumor markers and improves patient quality of life, supporting its broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.